UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-7772
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer ; day:28 ; month:12 ; year:2015 ; pages:1-8
International journal of clinical oncology ; (28.12.2015), 1-8
- Urheber
-
Miyata, Yoshinori
- Beteiligte Personen und Organisationen
-
Touyama, Tetsuo
Kusumi, Takaya
Morita, Yoshitaka
Mizunuma, Nobuyuki
Taniguchi, Fumihiro
Manabe, Mitsuaki
SpringerLink (Online service)
- DOI
-
10.1007/s10147-015-0937-x
- URN
-
urn:nbn:de:1111-2016070422494
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:04 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Miyata, Yoshinori
- Touyama, Tetsuo
- Kusumi, Takaya
- Morita, Yoshitaka
- Mizunuma, Nobuyuki
- Taniguchi, Fumihiro
- Manabe, Mitsuaki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Pro-inflammatory cytokine ratios determine the clinical course of febrile neutropenia in children receiving chemotherapy
Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving Immunotherapy
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
Synthesis of UDP-glucose, UDP-glucuronic acid and NRP luminmide using permeabilized cells
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
UDP-Glucuronyltransferase
Structure : function relationship of UDP-sugar pyrophosphorylases
A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis
Depletion of UDP-glucose and UDP-galactose using a Degron system leads to growth cessation of Leishmania major
Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Pro-inflammatory cytokine ratios determine the clinical course of febrile neutropenia in children receiving chemotherapy
Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving Immunotherapy
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
Synthesis of UDP-glucose, UDP-glucuronic acid and NRP luminmide using permeabilized cells
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
UDP-Glucuronyltransferase
Structure : function relationship of UDP-sugar pyrophosphorylases
A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis
Depletion of UDP-glucose and UDP-galactose using a Degron system leads to growth cessation of Leishmania major
Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Pro-inflammatory cytokine ratios determine the clinical course of febrile neutropenia in children receiving chemotherapy
Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving Immunotherapy
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
Synthesis of UDP-glucose, UDP-glucuronic acid and NRP luminmide using permeabilized cells
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
UDP-Glucuronyltransferase
Structure : function relationship of UDP-sugar pyrophosphorylases
A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis